1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Sales 2017-2028 2.1.2 World Current & Future Analysis for Glucagon-like peptide 1 (GLP-1)-based Therapies by Geographic Region, 2017, 2022 & 2028 2.1.3 World Current & Future Analysis for Glucagon-like peptide 1 (GLP-1)-based Therapies by Country/Region, 2017, 2022 & 2028 2.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Segment by Type 2.2.1 Exenatied 2.2.2 Liraglutide 2.2.3 Lixisenatide 2.2.4 Albiglutide 2.2.5 Dulaglutide 2.3 Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type 2.3.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2017-2022) 2.3.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue and Market Share by Type (2017-2022) 2.3.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sale Price by Type (2017-2022) 2.4 Glucagon-like peptide 1 (GLP-1)-based Therapies Segment by Application 2.4.1 Hospital 2.4.2 Pharmacy 2.5 Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application 2.5.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sale Market Share by Application (2017-2022) 2.5.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue and Market Share by Application (2017-2022) 2.5.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sale Price by Application (2017-2022) 3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies by Company 3.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Breakdown Data by Company 3.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Sales by Company (2020-2022) 3.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Company (2020-2022) 3.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Revenue by Company (2020-2022) 3.2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Company (2020-2022) 3.2.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Company (2020-2022) 3.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sale Price by Company 3.4 Key Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Product Location Distribution 3.4.2 Players Glucagon-like peptide 1 (GLP-1)-based Therapies Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022) 3.6 New Products and Potential Entrants 3.7 Mergers & Acquisitions, Expansion 4 World Historic Review for Glucagon-like peptide 1 (GLP-1)-based Therapies by Geographic Region 4.1 World Historic Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Geographic Region (2017-2022) 4.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Sales by Geographic Region (2017-2022) 4.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Revenue by Geographic Region 4.2 World Historic Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country/Region (2017-2022) 4.2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Sales by Country/Region (2017-2022) 4.2.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Revenue by Country/Region 4.3 Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth 4.4 APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth 4.5 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth 4.6 Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth 5 Americas 5.1 Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country 5.1.1 Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2017-2022) 5.1.2 Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2017-2022) 5.2 Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type 5.3 Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region 6.1.1 APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2017-2022) 6.1.2 APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region (2017-2022) 6.2 APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type 6.3 APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application 6.4 China 6.5 Japan 6.6 South Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 China Taiwan 7 Europe 7.1 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies by Country 7.1.1 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2017-2022) 7.1.2 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2017-2022) 7.2 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type 7.3 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies by Country 8.1.1 Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2017-2022) 8.1.2 Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2017-2022) 8.2 Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type 8.3 Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Manufacturing Cost Structure Analysis 10.1 Raw Material and Suppliers 10.2 Manufacturing Cost Structure Analysis of Glucagon-like peptide 1 (GLP-1)-based Therapies 10.3 Manufacturing Process Analysis of Glucagon-like peptide 1 (GLP-1)-based Therapies 10.4 Industry Chain Structure of Glucagon-like peptide 1 (GLP-1)-based Therapies 11 Marketing, Distributors and Customer 11.1 Sales Channel 11.1.1 Direct Channels 11.1.2 Indirect Channels 11.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Distributors 11.3 Glucagon-like peptide 1 (GLP-1)-based Therapies Customer 12 World Forecast Review for Glucagon-like peptide 1 (GLP-1)-based Therapies by Geographic Region 12.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Forecast by Region 12.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Forecast by Region (2023-2028) 12.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Revenue Forecast by Region (2023-2028) 12.2 Americas Forecast by Country 12.3 APAC Forecast by Region 12.4 Europe Forecast by Country 12.5 Middle East & Africa Forecast by Country 12.6 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Forecast by Type 12.7 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Forecast by Application 13 Key Players Analysis 13.1 Novo Nordisk 13.1.1 Novo Nordisk Company Information 13.1.2 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product Offered 13.1.3 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue, Price and Gross Margin (2020-2022) 13.1.4 Novo Nordisk Main Business Overview 13.1.5 Novo Nordisk Latest Developments 13.2 AstraZeneca 13.2.1 AstraZeneca Company Information 13.2.2 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product Offered 13.2.3 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue, Price and Gross Margin (2020-2022) 13.2.4 AstraZeneca Main Business Overview 13.2.5 AstraZeneca Latest Developments 13.3 Eli Lily 13.3.1 Eli Lily Company Information 13.3.2 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product Offered 13.3.3 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue, Price and Gross Margin (2020-2022) 13.3.4 Eli Lily Main Business Overview 13.3.5 Eli Lily Latest Developments 13.4 GSK 13.4.1 GSK Company Information 13.4.2 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product Offered 13.4.3 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue, Price and Gross Margin (2020-2022) 13.4.4 GSK Main Business Overview 13.4.5 GSK Latest Developments 13.5 Sanofi 13.5.1 Sanofi Company Information 13.5.2 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product Offered 13.5.3 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue, Price and Gross Margin (2020-2022) 13.5.4 Sanofi Main Business Overview 13.5.5 Sanofi Latest Developments 13.6 Bristol-Myers Squibb 13.6.1 Bristol-Myers Squibb Company Information 13.6.2 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product Offered 13.6.3 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Revenue, Price and Gross Margin (2020-2022) 13.6.4 Bristol-Myers Squibb Main Business Overview 13.6.5 Bristol-Myers Squibb Latest Developments 14 Research Findings and Conclusion

List of Tables Table 1. Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions) Table 2. Glucagon-like peptide 1 (GLP-1)-based Therapies Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions) Table 3. Major Players of Exenatied Table 4. Major Players of Liraglutide Table 5. Major Players of Lixisenatide Table 6. Major Players of Albiglutide Table 7. Major Players of Dulaglutide Table 8. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2017-2022) & (Units) Table 9. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2017-2022) Table 10. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Type (2017-2022) & ($ million) Table 11. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Type (2017-2022) Table 12. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sale Price by Type (2017-2022) & (US$/Unit) Table 13. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2017-2022) & (Units) Table 14. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2017-2022) Table 15. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Application (2017-2022) Table 16. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Application (2017-2022) Table 17. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sale Price by Application (2017-2022) & (US$/Unit) Table 18. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Company (2020-2022) & (Units) Table 19. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Company (2020-2022) Table 20. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Company (2020-2022) ($ Millions) Table 21. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Company (2020-2022) Table 22. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sale Price by Company (2020-2022) & (US$/Unit) Table 23. Key Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Producing Area Distribution and Sales Area Table 24. Players Glucagon-like peptide 1 (GLP-1)-based Therapies Products Offered Table 25. Glucagon-like peptide 1 (GLP-1)-based Therapies Concentration Ratio (CR3, CR5 and CR10) & (2020-2022) Table 26. New Products and Potential Entrants Table 27. Mergers & Acquisitions, Expansion Table 28. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Geographic Region (2017-2022) & (Units) Table 29. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share Geographic Region (2017-2022) Table 30. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Geographic Region (2017-2022) & ($ millions) Table 31. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Geographic Region (2017-2022) Table 32. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country/Region (2017-2022) & (Units) Table 33. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country/Region (2017-2022) Table 34. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country/Region (2017-2022) & ($ millions) Table 35. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country/Region (2017-2022) Table 36. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2017-2022) & (Units) Table 37. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country (2017-2022) Table 38. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2017-2022) & ($ Millions) Table 39. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country (2017-2022) Table 40. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2017-2022) & (Units) Table 41. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2017-2022) Table 42. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2017-2022) & (Units) Table 43. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2017-2022) Table 44. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2017-2022) & (Units) Table 45. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region (2017-2022) Table 46. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region (2017-2022) & ($ Millions) Table 47. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Region (2017-2022) Table 48. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2017-2022) & (Units) Table 49. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2017-2022) Table 50. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2017-2022) & (Units) Table 51. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2017-2022) Table 52. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2017-2022) & (Units) Table 53. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country (2017-2022) Table 54. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2017-2022) & ($ Millions) Table 55. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country (2017-2022) Table 56. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2017-2022) & (Units) Table 57. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2017-2022) Table 58. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2017-2022) & (Units) Table 59. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2017-2022) Table 60. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2017-2022) & (Units) Table 61. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country (2017-2022) Table 62. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2017-2022) & ($ Millions) Table 63. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country (2017-2022) Table 64. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2017-2022) & (Units) Table 65. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2017-2022) Table 66. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2017-2022) & (Units) Table 67. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2017-2022) Table 68. Key Market Drivers & Growth Opportunities of Glucagon-like peptide 1 (GLP-1)-based Therapies Table 69. Key Market Challenges & Risks of Glucagon-like peptide 1 (GLP-1)-based Therapies Table 70. Key Industry Trends of Glucagon-like peptide 1 (GLP-1)-based Therapies Table 71. Glucagon-like peptide 1 (GLP-1)-based Therapies Raw Material Table 72. Key Suppliers of Raw Materials Table 73. Glucagon-like peptide 1 (GLP-1)-based Therapies Distributors List Table 74. Glucagon-like peptide 1 (GLP-1)-based Therapies Customer List Table 75. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Region (2023-2028) & (Units) Table 76. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Forecast by Region Table 77. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Forecast by Region (2023-2028) & ($ millions) Table 78. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share Forecast by Region (2023-2028) Table 79. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Country (2023-2028) & (Units) Table 80. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Forecast by Country (2023-2028) & ($ millions) Table 81. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Region (2023-2028) & (Units) Table 82. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Forecast by Region (2023-2028) & ($ millions) Table 83. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Country (2023-2028) & (Units) Table 84. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Forecast by Country (2023-2028) & ($ millions) Table 85. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Country (2023-2028) & (Units) Table 86. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Forecast by Country (2023-2028) & ($ millions) Table 87. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Type (2023-2028) & (Units) Table 88. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share Forecast by Type (2023-2028) Table 89. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Forecast by Type (2023-2028) & ($ Millions) Table 90. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share Forecast by Type (2023-2028) Table 91. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Forecast by Application (2023-2028) & (Units) Table 92. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share Forecast by Application (2023-2028) Table 93. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Forecast by Application (2023-2028) & ($ Millions) Table 94. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share Forecast by Application (2023-2028) Table 95. Novo Nordisk Basic Information, Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturing Base, Sales Area and Its Competitors Table 96. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product Offered Table 97. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022) Table 98. Novo Nordisk Main Business Table 99. Novo Nordisk Latest Developments Table 100. AstraZeneca Basic Information, Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturing Base, Sales Area and Its Competitors Table 101. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product Offered Table 102. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022) Table 103. AstraZeneca Main Business Table 104. AstraZeneca Latest Developments Table 105. Eli Lily Basic Information, Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturing Base, Sales Area and Its Competitors Table 106. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product Offered Table 107. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022) Table 108. Eli Lily Main Business Table 109. Eli Lily Latest Developments Table 110. GSK Basic Information, Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturing Base, Sales Area and Its Competitors Table 111. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product Offered Table 112. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022) Table 113. GSK Main Business Table 114. GSK Latest Developments Table 115. Sanofi Basic Information, Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturing Base, Sales Area and Its Competitors Table 116. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product Offered Table 117. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022) Table 118. Sanofi Main Business Table 119. Sanofi Latest Developments Table 120. Bristol-Myers Squibb Basic Information, Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturing Base, Sales Area and Its Competitors Table 121. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product Offered Table 122. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022) Table 123. Bristol-Myers Squibb Main Business Table 124. Bristol-Myers Squibb Latest Developments List of Figures Figure 1. Picture of Glucagon-like peptide 1 (GLP-1)-based Therapies Figure 2. Glucagon-like peptide 1 (GLP-1)-based Therapies Report Years Considered Figure 3. Research Objectives Figure 4. Research Methodology Figure 5. Research Process and Data Source Figure 6. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Growth Rate 2017-2028 (Units) Figure 7. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth Rate 2017-2028 ($ Millions) Figure 8. Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2021 & 2028) & ($ millions) Figure 9. Product Picture of Exenatied Figure 10. Product Picture of Liraglutide Figure 11. Product Picture of Lixisenatide Figure 12. Product Picture of Albiglutide Figure 13. Product Picture of Dulaglutide Figure 14. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type in 2021 Figure 15. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Type (2017-2022) Figure 16. Glucagon-like peptide 1 (GLP-1)-based Therapies Consumed in Hospital Figure 17. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market: Hospital (2017-2022) & (Units) Figure 18. Glucagon-like peptide 1 (GLP-1)-based Therapies Consumed in Pharmacy Figure 19. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market: Pharmacy (2017-2022) & (Units) Figure 20. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2017-2022) Figure 21. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Application in 2021 Figure 22. Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market by Company in 2021 ($ Million) Figure 23. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Company in 2021 Figure 24. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Geographic Region (2017-2022) Figure 25. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Geographic Region in 2021 Figure 26. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region (2017-2022) Figure 27. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country/Region in 2021 Figure 28. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales 2017-2022 (Units) Figure 29. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue 2017-2022 ($ Millions) Figure 30. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales 2017-2022 (Units) Figure 31. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue 2017-2022 ($ Millions) Figure 32. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales 2017-2022 (Units) Figure 33. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue 2017-2022 ($ Millions) Figure 34. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales 2017-2022 (Units) Figure 35. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue 2017-2022 ($ Millions) Figure 36. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country in 2021 Figure 37. Americas Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country in 2021 Figure 38. United States Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2017-2022 ($ Millions) Figure 39. Canada Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2017-2022 ($ Millions) Figure 40. Mexico Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2017-2022 ($ Millions) Figure 41. Brazil Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2017-2022 ($ Millions) Figure 42. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region in 2021 Figure 43. APAC Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Regions in 2021 Figure 44. China Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2017-2022 ($ Millions) Figure 45. Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2017-2022 ($ Millions) Figure 46. South Korea Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2017-2022 ($ Millions) Figure 47. Southeast Asia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2017-2022 ($ Millions) Figure 48. India Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2017-2022 ($ Millions) Figure 49. Australia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2017-2022 ($ Millions) Figure 50. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country in 2021 Figure 51. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country in 2021 Figure 52. Germany Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2017-2022 ($ Millions) Figure 53. France Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2017-2022 ($ Millions) Figure 54. UK Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2017-2022 ($ Millions) Figure 55. Italy Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2017-2022 ($ Millions) Figure 56. Russia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2017-2022 ($ Millions) Figure 57. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Country in 2021 Figure 58. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Country in 2021 Figure 59. Egypt Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2017-2022 ($ Millions) Figure 60. South Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2017-2022 ($ Millions) Figure 61. Israel Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2017-2022 ($ Millions) Figure 62. Turkey Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2017-2022 ($ Millions) Figure 63. GCC Country Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Growth 2017-2022 ($ Millions) Figure 64. Manufacturing Cost Structure Analysis of Glucagon-like peptide 1 (GLP-1)-based Therapies in 2021 Figure 65. Manufacturing Process Analysis of Glucagon-like peptide 1 (GLP-1)-based Therapies Figure 66. Industry Chain Structure of Glucagon-like peptide 1 (GLP-1)-based Therapies Figure 67. Channels of Distribution Figure 68. Distributors Profiles